insurers glp-1 coverage news Insurance Statistics 2026 | Employer, Medicare & Medicaid Data Patients Face New Barriers for

Source: Polaris Market Research Analysis Industry Developments February 2025: Biocon launched its GLP-1 peptide liraglutide in the UK under two brand names: Liraglutide Biocon (for diabetes, similar to Victoza) and Biolide (for chronic weight management, similar to Saxenda)

Terawaki Y, Nomiyama T, Takahashi H, Tsutsumi Y, Murase K, Nagaishi R, et al

& Westermark, G

In terms of weight loss at comparable time points, tirzepatide consistently outperforms semaglutide in clinical trials

Well, the existing data do not show that. Patients often stop using GLP-1s within a year for a variety of reasons, including cost, meeting their goal weight or gastrointestinal side effects

NOT FOR HUMAN CONSUMPTION , medical, or veterinary use